Multidrug-resistant tuberculosis: A menace that threatens to destabilize tuberculosis control

Chest

Volumn 130, Issue 1, 2006, Pages 261-272

  Sharma, Surendra K ^a   Mohan, Alladi ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diagnosis; Epidemiology; Multidrug resistant tuberculosis; Predictors for development; Prognostic factors; Treatment; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ALPHA INTERFERON; AMIKACIN; AMINOSALICYLIC ACID; BACTERIAL DNA; BCG VACCINE; CAPREOMYCIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GAMMA INTERFERON; GATIFLOXACIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; TELITHROMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ACIDOSIS; ACNE; AGRANULOCYTOSIS; ANOREXIA; APLASTIC ANEMIA; ARTICLE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BCG VACCINATION; BEHAVIOR DISORDER; COMORBIDITY; CONFUSION; CONVULSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EARLY DIAGNOSIS; EPIGASTRIC DISCOMFORT; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; GOITER; GYNECOMASTIA; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEMOLYTIC ANEMIA; HEPATITIS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSALIVATION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; IMMUNOTHERAPY; IMPOTENCE; INJECTION SITE PAIN; INSOMNIA; LIVER DYSFUNCTION; LIVER TOXICITY; LUPUS LIKE SYNDROME; MENSTRUATION DISORDER; MOOD DISORDER; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NUTRITIONAL SUPPORT; OPTIC NEURITIS; OTOTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SKIN DISEASE; SKIN MANIFESTATION; SLURRED SPEECH; SUICIDAL BEHAVIOR; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT PLANNING; TREMOR; TUBERCULOSIS; VERTIGO; VOMITING;

EID: 33746342137     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.1.261     Document Type: Article

References (68)

1. World Health Organization. Tuberculosis: the global burden; global TB fact sheet 2005. Available at: http://www.who.int/ tb/publications/ tb_global_facts_sep05_en.pdf. Accessed December 25, 2005
2. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005; 73-74:17-24
3. Sharma SK, Mohan A. Multidrug-resistant tuberculosis. Indian J Med Res 2004; 120:354-376
4. Frieden TR, Munsiff SS. The DOTS strategy for controlling the global tuberculosis epidemic. Clin Chest Med 2005; 26:197-205
5. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514-1521
6. Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993; 168:1052-1055
7. World Health Organization, International Union Against Tuberculosis and Lung Disease. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1999-2002: anti-tuberculosis drug resistance in the world; third global report. Geneva, Switzerland: World Health Organization, 2004
8. Zignol M. Incidence of multidrug-resistant tuberculosis: 2003 global estimates. Available at: http://www.stoptb.org/wg/ dots_plus/meetings.asp. Accessed January 10, 2006
9. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3-29
10. Brown TJ, Herrera-Leon L, Anthony RM, et al. The use of macroarrays for the identification of MDR Mycobacterium tuberculosis. J Microbiol Methods 2006; 65:294-300
11. Sreevatsan S, Pan X, Zhang Y, et al. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997; 41:600-606
12. Traore H, Fissette K, Bastian I, et al. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis 2000; 4:481-484
13. Bastian I, Rigouts L, Van Deun A, et al. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ 2000; 78:238-251
14. Casal M, Vaquero M, Rinder H, et al. A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist 2005; 11:62-67
15. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5:887-893
16. Alrajhi AA, Abdulwahab S, Almodovar E, et al. Risk factors for drug-resistant Mycobacterium tuberculosis in Saudi Arabia. Saudi Med J 2002; 23:305-310
17. Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Revised national tuberculosis control programme: DOTS-Plus guidelines. Available at: http://www.tbcindia.org/ pdfs/ DOTS-Plus%20Guidelines.pdf. Accessed March 31, 2006
18. Sharma SK, Mohan A. Scientific basis of directly observed treatment, short-course (DOTS). J Indian Med Assoc 2003; 101:157-158, 166
19. Crofton J, Chaulet P, Maher D, et al. Guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization, 1997
20. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365:1239-1245
21. Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet 1999; 353:969-973
22. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-2545
23. Ahmed N, Hasnain SE. Genomics of Mycobacterium tuberculosis: old threats & new trends. Indian J Med Res 2004; 120:207-212
24. Cox HS, Kubica T, Doshetov D, et al. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res 2005; 6:134
25. Kubica T, Agzamova R, Wright A, et al. The Beijing genotype is a major cause of drug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis 2005; 9:646-653
26. Singh UB, Suresh N, Bhanu NV, et al. Predominant tuberculosis spoligotypes, Delhi, India. Emerg Infect Dis 2004; 10:1138-1142
27. Putman M, van Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 2000; 64:672-693
28. Siddiqi N, Das R, Pathak N, et al. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 2004; 32:109-111
29. Sharma SK, Turaga KK, Balamurugan A, et al. Clinical and genetic risk factors for the development of multidrug-resistant tuberculosis in non-HIV infected at a tertiary care center in India: a case-control study. Infect Genet Evol 2003; 3:183-188
30. Kim HS, Park MH, Song EY, et al. Association of HLA-DR and HLA-DQ genes with susceptibility to pulmonary tuberculosis in Koreans: preliminary evidence of associations with drug resistance, disease severity, and disease recurrence. Hum Immunol 2005; 66:1074-1081
31. Asch S, Knowles L, Rai A, et al. Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis. Am J Respir Crit Care Med 1996; 153:1708-1710
32. Spellman CW, Matty KJ, Weis SE. A survey of drug resistant Mycobacterium tuberculosis and its relationship to HIV infection. AIDS 1998; 12:191-195
33. Caws M, Drobniewski FA, Molecular techniques in the diagnosis of Mycobacterium tuberculosis and the detection of drug resistance. Ann N Y Acad Sci 2001; 953:138-145
34. Albert H, Trollip AP, Mole RJ, et al. Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF, a manual phage-based test. Int J Tuberc Lung Dis 2002; 6:523-528
35. Cohn DL, O'Brien RJ. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998; 2:16-26
36. Supply P, Lesjean S, Savine E, et al. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J Clin Microbiol 2001; 39:3563-3571
37. Ahmed N, Alam M, Rao KR, et al. Molecular genotyping of a large, multicentric collection of tubercle bacilli indicates geographical partitioning of strain variation and has implications for global epidemiology of Mycobacterium tuberculosis. J Clin Microbiol 2004; 42:3240-3247
38. Soini H, Musser JM. Molecular diagnosis of mycobacteria. Clin Chem 2001; 47:809-814
39. Parsons LM, Somoskovi A, Urbanczik R, et al. Laboratory diagnostic aspects of drug resistant tuberculosis. Front Biosci 2004; 9:2086-2105
40. Gryadunov D, Mikhailovich V, Lapa S, et al. Evaluation of hybridisation on oligonucleotide microarrays for analysis of drug-resistant Mycobacterium tuberculosis. Clin Microbiol Infect 2005; 11:531-539
41. Sharma SK, Liu JJ. Progress of directly observed treatment, short-course (DOTS) in global TB control. Lancet. 2006; 367:951-952
42. World Health Organization, Stop TB Department. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva, Switzerland: World Health Organization, 2003
43. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America; treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662
44. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119-128
45. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9:640-645
46. Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency in partnerships for health: introducing the Green Light Committee. Trop Med Int Health 2002; 7:970-976
47. Kim JY, Mukherjee JS, Rich ML, et al. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis (Edinb) 2003; 83:59-65
48. Gupta R, Espinal M. Stop TB Working Group on DOTS-Plus for MDR-TB: a prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003; 7:410-414
49. Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 2005; 331:1364
50. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365:318-326
51. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8:1382-1384
52. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324
53. Drobniewski F, Eltringham I, Graham C, et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 2002; 57:810-816
54. Flament-Saillour M, Robert J, Jarlier V, et al. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593
55. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345:170-174
56. O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005; 26:327-340
57. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962-966
58. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005; 49:2294-2301
59. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-227
60. Gupta P, Hameed S, Jain R. Ring-substituted imidazoles as a new class of anti-tuberculosis agents. Eur J Med Chem 2004; 39:805-814
61. Etemadi A, Farid R, Stanford JL. Immunotherapy for drug-resistant tuberculosis. Lancet 1992; 340:1360-1361
62. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9:1701-1709
63. Patel N, Deshpande MM, Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 2002; 100:191-193
64. Patel N, Trapathi SB. Improved cure rates in pulmonary tuberculosis category II (retreatment) with Mycobacterium w. J Indian Med Assoc 2003; 101:680, 682
65. Granich R, Binkin NJ, Jarvis WR, et al. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. Geneva, Switzerland: World Health Organization, 1999
66. Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1-141
67. Fraser A, Paul M, Attamna A, et al. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006; 10:19-23
68. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999; this is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC)-this statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:8221-8247